RJFSA
SRPT icon

Raymond James Financial Services Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22,800
Closed -$20K – 2693
2017
Q3 		$20K Buy
+22,800
New +$911K ﹤0.01% 2506
2016
Q4 		– Sell
-13,500
Closed -$7K – 2431
2016
Q3 		$7K Buy
+13,500
New +$408K ﹤0.01% 2294

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raymond James Financial Services Advisors's SRPT Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Sarepta Therapeutics (SRPT) stake by 0.96% in Q3 2024, buying an estimated $10.2K and bringing the position to 7,787 shares worth $973K. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Raymond James Financial Services Advisors first reported a position in SRPT in Q3 2016 and has held it in 33 quarters since. The position peaked at $2.42M in Q2 2021. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Raymond James Financial Services Advisors held 7,787 shares of Sarepta Therapeutics worth $973K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 74 Sarepta Therapeutics shares in Q3 2024, an estimated $10.2K.
  • Sarepta Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2185 holding.
  • Raymond James Financial Services Advisors first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 33 quarters since.
  • Raymond James Financial Services Advisors's Sarepta Therapeutics position peaked at $2.42M in Q2 2021.
  • 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.